Providence St. Joseph Health

Providence St. Joseph Health Digital Commons
Articles, Abstracts, and Reports
10-1-2017

Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report
from the PsA Workshop at OMERACT 2016.
Ana-Maria Orbai
Maarten de Wit
Philip Mease
Kristina Callis Duffin
Musaab Elmamoun

See next page for additional authors

Follow this and additional works at: https://digitalcommons.psjhealth.org/publications
Part of the Rheumatology Commons

Authors
Ana-Maria Orbai, Maarten de Wit, Philip Mease, Kristina Callis Duffin, Musaab Elmamoun, William Tillett,
Willemina Campbell, Oliver FitzGerald, Dafna D Gladman, Niti Goel, Laure Gossec, Pil Hoejgaard, Ying Ying
Leung, Chris Lindsay, Vibeke Strand, Désirée M van der Heijde, Bev Shea, Robin Christensen, Laura Coates,
Lihi Eder, Neil McHugh, Umut Kalyoncu, Ingrid Steinkoenig, and Alexis Ogdie

HHS Public Access
Author manuscript
Author Manuscript

J Rheumatol. Author manuscript; available in PMC 2017 October 03.
Published in final edited form as:
J Rheumatol. 2017 October ; 44(10): 1522–1528. doi:10.3899/jrheum.160904.

Updating the Psoriatic Arthritic Core Domain Set: A Report from
the PsA Workshop at OMERACT 2016
Ana-Maria Orbai, MD, MHS,
Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore USA

Author Manuscript

Maarten de Wit, PhD [Patient Research Partner],
VU Medical Centre, Amsterdam, The Netherlands
Philip Mease, MD,
Rheumatology Research, Swedish Medical Center and University of Washington School of
Medicine, Seattle, WA, USA
Kristina Callis Duffin, MD,
Department of Dermatology, University of Utah, Salt Lake City, Utah, USA
Musaab Elmamoun, MBBS, MRCPI,
Dept of Rheumatology, St. Vincents University Hospital and Conway Institute for Biomolecular
Research, University College Dublin, Ireland
William Tillett, BSc, MB ChB, PhD, MRCP,
Royal National Hospital for Rheumatic Diseases, Bath, UK

Author Manuscript

Willemina Campbell, BEd LLB [Patient Research Partner],
Toronto Western Hospital, Toronto, Ontario, Canada
Oliver FitzGerald, MD, FRCPI, FRCP(UK),
Newman Clinical Research Professor, Dept of Rheumatology, St. Vincents University Hospital
and Conway Institute for Biomolecular Research, University College Dublin, Ireland
Dafna Gladman, MD, FRCPC [Professor],
Medicine, University of Toronto; Senior Scientist, Krembil Research Institute; Director, Psoriatic
Arthritis Program, University Health Network; Toronto, Ontario, Canada
Niti Goel, MD [Patient Research Partner],
Quintiles, Duke University School of Medicine. Durham, NC, USA

Author Manuscript

Laure Gossec, MD, PhD,
Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé
Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of
Rheumatology, Paris, France
Pil Hoejgaard, MD,
The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark

Corresponding Author: Ana-Maria Orbai, MD, MHS, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B,
Baltimore, MD, USA 21224; Phone 410-550-8231; Fax 410-550-5601; aorbai1@jhmi.edu.

Orbai et al.

Page 2

Author Manuscript

Ying Ying Leung, MD, PhD,
Department of Rheumatology and Immunology, Singapore General Hospital, Singapore
Chris Lindsay, Pharm.D [Patient Research Partner],
Thousand Oaks, CA, USA
Vibeke Strand, MD,
Division of Immunology, Stanford University, Palo Alto, CA, USA
Désirée van der Heijde, MD, PhD,
Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
Bev Shea, Robin Christensen, Laura Coates, MB ChB, PhD,
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds
Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds UK

Author Manuscript

Lihi Eder, MD, PhD,
Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto,
Ontario, Canada
Neil McHugh, MBChB, MD, FRCP, FRCPath,
Royal National Hospital for Rheumatic Diseases, Bath, UK
Umut Kalyoncu, MD,
Department of Internal Medicine, Division of Rheumatology, Hacettepe University Ankara, Turkey
Ingrid Steinkoenig, BA [Patient Research Partner], and
Cleveland Clinic, Cleveland, OH, USA

Author Manuscript

Alexis Ogdie, MD, MSCE
University of Pennsylvania, Philadelphia, PA, USA

Abstract
Objectives—The current psoriatic arthritis (PsA) Core Domain Set defines core domains to be
measured in randomized controlled trials (RCTs) and longitudinal observational studies (LOS) and
was published in 2006. At the Outcome Measures in Rheumatology (OMERACT) meeting in
2014, researchers, clinicians and patients unanimously voted for updating the PsA Core Domain
Set to include the patient perspective in accordance with OMERACT Filter 2.0. Herein we report
the proceedings of the PsA Workshop at the OMERACT meeting in 2016 including studies
presented in the plenary, results of breakout group discussions, and final voting and endorsement
of the 2016 updated PsA Core Domain Set.
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Methods—We conducted research to develop the updated PsA Core Domain Set. At OMERACT
2016 this work was presented, discussed in breakout groups and the updated PsA core domain set
was voted on and endorsed by OMERACT participants.
Results—The updated PsA Core Domain Set includes: musculoskeletal disease activity, skin
disease activity, fatigue, pain, patient global, physical function, health related quality of life and
systemic inflammation which are recommended for all RCTs and LOS). Economic cost, emotional
well-being, participation and structural damage are important but not required in all RCTs and
LOS. Independence, sleep, stiffness and treatment burden on the research agenda.
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Conclusion—The updated PsA Core Domain Set was endorsed at OMERACT 2016. Next steps
for the PsA working group include evaluation of available outcome measures for each of the core
domains and development of a PsA core outcome measurement set.
Key indexing terms
psoriatic arthritis; core set; outcome measures

INTRODUCTION
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STATEMENT OF CONTRIBUTION TO THE LITERATURE: This paper describes the
the research work streams that led to the updated PsA Core domain set and its final
endorsement at OMERACT 2016. The 2016 updated PsA Core Domain Set will allow the
beginning of patient-centered and evidence-based selection of a Core Outcome
Measurement set for future PsA clinical trials. This paper uniquely describes the
OMERACT 2016 conference process which led to the endorsement of the final updated
2016 PsA Core domain set and has not been submitted elsewhere.
The updated 2016 PsA Core Domain Set contains the following revised or new domains
compared to the 2006 core set:
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•

MSK disease activity (revised to include peripheral joints, dactylitis, enthesitis
and spine symptoms)

•

Skin activity (revised to include skin and nails)

•

Fatigue

•

Systemic inflammation.

•

Participation, Emotional well-being, Structural damage and Economic cost are
designated important and are not required in all clinical trials.
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The purpose of disease core sets is to standardize measurement and reporting of outcomes in
randomized controlled trials (RCTs) and longitudinal observational studies (LOS).
Implementation and reporting of disease core sets in RCTs is key to generating high quality
evidence to support useful treatment recommendations (1). Outcome Measures in
Rheumatology (OMERACT) pioneered disease core set development and refined their
methodology based on evidence (2, 3). In 2014, OMERACT presented and published Filter
2.0 outlining a methodologically rigorous process for defining core domain sets (5) based on
early inclusion of the views of key stakeholders, especially patients and iterative, evidencedriven consensus among stakeholders. At the OMERACT 2014 conference, participants
recognized the need to update the PsA Core Domain set based on the new OMERACT filter
and, integral to this process, to incorporate the voice of patients and rapidly developing
scientific knowledge about the disease and the measurement of PsA (6, 7). OMERACT 2014
attendees (including researchers, patient partners and clinicians) voted to update the PsA
core domain set (100% voted yes) and additionally voted to include fatigue (72%) and
dactylitis (70%) in the core set (8).
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Since the OMERACT 2014 meeting, the GRAPPA-OMERACT PsA working group
conducted research projects (9) to identify domains important to patients and physicians for
the PsA core domain set update. This paper summarizes results presented at the OMERACT
2016 PsA workshop and breakout group discussions and the subsequent endorsement of the
updated PsA core domain set.

Summary of research conducted in preparation for OMERACT 2016
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The PsA working group conducted the following research projects: 1) a systematic literature
review (SLR) in Pubmed and EMBASE to identify domains measured in PsA RCTs, LOS
and registries; 2) international focus groups with patients with PsA to identify domains; 3)
international patient and physician surveys; and 4) a consensus meeting held March 12, 2016
in Jersey City, NJ, US with patients and physicians using the nominal group technique
(NGT) to draft a PsA core domain set. Detailed methods and results are presented in
separate manuscripts (9, 10) (reference to be added later).
Studies were approved by the Johns Hopkins Institutional Review Board (IRB), Baltimore,
MD, USA (IRB00093948 and NA_00066663), the National Research Ethics Service
Committee North West – Haydock, UK (REC reference: 15/NW/0609) and the online survey
study was accorded exempt status at the University of Pennsylvania IRB, Philadelphia, PA,
USA.

Author Manuscript

The SLR has been published and showed the measurement of the complete 2006 PsA core
domain set increased from being performed in 24% of RCTs (from 2005 to 2010) to 59% of
RCTs (from 2010 to 2015) (10, 11). Twenty-four domains were identified from the SLR,
with 18 measured in addition to the core set (Figure 1). The changes over time are likely
related to dissemination of the PsA core set, recognition of the importance of fatigue,
productivity and other aspects of life impact for patients (8, 12–14), and availability of
outcome measures for domains such as dactylitis (15).
Qualitative research was conducted to identify domains directly from patients to include
their perspective at the inception of the process (16). Two focus group studies were
conducted: one international (16 focus groups with 89 patients in total in Australia, Brazil,
France, Netherlands, Singapore and US) and one multicenter study in the UK (8 focus
groups with 41 patients). Qualitative data analysis of each study identified patient domains.
Across both studies there were 34 unique patient domains.

Author Manuscript

The 24 domains from the SLR and 34 domains from international focus groups were then
combined into a list of 39 unique domains. Patients (n=50) recruited from rheumatology
clinics and patient organizations and physicians (n=75) recruited through GRAPPA rated
domains via electronic surveys running in parallel. Results were discussed at the NGT
consensus meeting held March 12, 2016 with 12 patients and 12 physicians. The NGT
method allowed stakeholders to prioritize items ensuring the inclusion of all participants’
opinions (17). At the end of the consensus meeting a draft core domain set was agreed upon
and included 10 domains: musculoskeletal (MSK) disease activity (peripheral joints,
enthesitis, dactylitis and spine symtoms), skin disease activity (skin and nails), pain, patient
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global (patient reported disease related health status), physical function, participation,
emotional well-being, fatigue, systemic inflammation, structural damage (to be measured at
least once during a new drug development program for PsA). A domain considered
important but not required in all RCTs and LOS was economic cost (societal financial
impact not otherwise captured by participation and work/employment domains). The NGT
core domain set was then rated in a second electronic survey completed in parallel by
patients and physicians. Based on results from the second round of surveys the draft core
domain set included nine domains: MSK disease activity, skin disease activity, pain, patient
global, physical function, participation, fatigue, systemic inflammation, structural damage
(to be measured at least once during a new drug development program for PsA) (Table 1).
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Patients were involved at all levels as research participants, patient researchers (conducting
focus groups and analyzing data), or patient research partners (PRPs; assisting in the high
level conduct of the research) in each of the work streams (Table 2). One PRP was a member
of the steering committee for the working group (reference to be added later).

Working group meeting at OMERACT 2016
A working group meeting was held at OMERACT prior to the PsA Workshop for final
review of the workshop presentation, breakout group organization and voting questions. At
this meeting decisions were made regarding the core domain set to be presented at the
workshop:
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1.

Structural damage was important but not required in all RCTs and LOS. This
was congruent with the NGT meeting where structural damage was
recommended to be measured once during the development of a new therapeutic
agent for PsA but not required in all RCTs.

2.

Health related quality of life (HRQoL) remained a core domain required in all
RCTs and LOS based on its presence in the 2006 core domain set.

3.

The group decided to hold two separate votes for participation: first for inclusion
in the core domain set (required in all RCTs and LOS) and second (if first not
agreed by 70%) for inclusion in the middle circle (important but not required in
all RCTs and LOS). Work/employment (included in participation) was rated high
in the first survey by both patients and physicians, and participation was in the
preliminary core set after the NGT meeting as well as rated high by patients in
the second survey. However, due feasibility concerns and overlap of participation
with the broader concept of HRQoL, we anticipated both may not be accepted in
the core set (and therefore the decision to hold two votes).

4.

Due to the importance of emotional well-being for patients, both in the NGT
meeting and also at this working group meeting, the group similarly decided to
first vote for inclusion of emotional well-being in the core set and second (if first
not agreed by 70%) vote for inclusion in the middle circle.

The group also agreed upon the final list of voting questions for the conclusion of the
workshop.
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OMERACT 2016 PsA workshop
The PsA workshop began with presentation of results, continued with eight breakout group
discussions running in parallel followed by reports from each breakout group, and concluded
with voting. Results from research conducted in preparation for OMERACT were presented
to workshop participants as above (Table 1).
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Breakout group discussions were facilitated by two people (one moderator and one reporter),
both of whom were either a member of the working group or experienced PsA or psoriasis
researchers. The four PsA working group PRPs were either a group moderator or reporter.
All breakout groups discussed each new or updated domain: participation, systemic
inflammation, MSK disease activity and skin activity, emotional well-being and structural
damage. Fatigue had been voted for inclusion in the core domain set by 72% of the
participants at the OMERACT 2014 conference (8) and was not discussed again. For each
domain breakout group participants were asked to provide arguments supporting inclusion in
the core domain set as well as perceived challenges. Throughout the process of developing
the core set and also in the breakout groups, discussion of how to best measure a particular
domain was discouraged as instruments were not felt to be relevant at this stage to the
decision on which domains to include. A summary of breakout group discussions is
presented in supplement Table 3.
Following the breakout group reporting in the plenary, OMERACT participants voted for
individual domains and this concluded the workshop (Table 4). The only modification to the
preliminary core set was movement of participation to the middle circle (important but not
required in all RCTs and LOS).
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OMERACT 2016 Final Plenary
At the OMERACT plenary the final PsA 2016 Core Domain Set was proposed for
endorsement and achieved consensus with a 90% vote from 130 participants at the
conference. The updated 2016 PsA core domain set includes the following outcomes
recommended for assessment in all RCTs and LOS (inner core): MSK disease activity, skin
disease activity, fatigue, pain, patient global, physical function, HRQoL and systemic
inflammation. The following outcomes (middle circle) are important but not required in all
RCTs/LOS: economic cost, emotional well-being, participation and structural damage.
Outcomes that need to be studied further due to their importance for people with PsA
include: independence, sleep, stiffness and treatment burden (Figure 2).
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Contextual factors for PsA are another important area that needs further study. Adverse
events are measured in every RCT and are part of the OMERACT outcome framework. The
updated 2016 PsA Core Domain Set addresses all areas of the OMERACT Filter 2.0
framework (Figure 3).

DISCUSSION
Psoriatic arthritis is a heterogeneous disease with tremendous impact on patients’ lives. At
OMERACT 2014 the GRAPPA-OMERACT PsA working group committed to updating the
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2006 PsA Core Domain set to incorporate the input of people living with PsA and advances
in the field. Candidate domains for the updated PsA Core Domain Set were obtained directly
from patients through international focus groups and an SLR of outcomes measured in PsA
RCTs, LOS and registries. During the surveys and consensus meeting with patients and
physicians, each domain presented for rating or discussion was accompanied by a clear
definition based on focus group patient participants’ descriptions and reviewed by the
working group including PRPs. We adopted this method to maximize understanding for all
participants and to minimize subjective interpretations during the surveys and the consensus
meeting.
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The concept of MSK disease activity which encompasses peripheral joints, enthesitis,
dactylitis and spine symptoms has been initially suggested in breakout groups at OMERACT
2014 (8) out of concerns for parsimony in the core set. This comprehensive definition for
MSK disease activity was fully supported at the consensus meeting with patients and
physicians and endorsed with majority vote at OMERACT 2016.
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Discussion at OMERACT 2016 focused particularly on the inclusion of participation and
emotional well-being. Participation (encompassing work and/or employment within and
outside the home, leisure activities, social activities and family roles) was defined congruent
with the ICF definition which is “involvement in a life situation” and distinct from activity
which implies “the execution of a task or action” (18). Ability to perform work (both paid
and unpaid) is an important outcome to patients and ranked highly in surveys with patients
conducted by our working group and also in the European League Against Rheumatism
(EULAR) led Psoriatic Arthritis Impact of Disease (PsAID) study (12). Estimates of
unemployment and work disability range from 20–50% and 16–39% respectively in clinical
trials and cohort studies (19) and appropriate therapy can improve aspects of participation
(20). Therefore participation has face validity and optimal measurement needs to be studied
further.
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Emotional well-being was defined as “feeling good about oneself” and may include
additional domains such as depressive mood, anxiety, embarrassment, self-worth,
frustration, and stress. During the NGT meeting, emotional well-being was highly relevant
to the management of PsA for patient participants. Previous studies suggested 20% of
patients with PsA have depression and one study found that 37% had anxiety (21). The best
way of measuring emotional well-being in patients with PsA has not been investigated. The
PsAID includes items on depression, anxiety and embarrassment and the Medical Outcomes
Survey Short Form-36 (SF-36) includes “mental health”, “role emotional”, “vitality” and
also “social functioning” domains (22). Following discussions at OMERACT 2016, and in
line with the second survey with patients and physicians it became clear that additional
research may be needed before emotional well-being might become an inner core element.
An aspect discussed for both participation and emotional well-being was conceptual overlap
with HRQoL. Concomitant measurement of all these concepts may be redundant and
demanding on responders. Another consideration is that patient participants in focus groups
described specific areas of PsA life impact. For this reason, for patients it may be difficult to
relate to overarching concepts like HRQoL when considering their treatment options. There
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was discussion to replace the generic construct of HRQoL with explicit domains that are
patient relevant: participation, fatigue and emotional well-being. This is an important area
for future research in PsA.
One concern raised at OMERACT 2016 was the number of domains and subdomains
mandatory in all future PsA RCTs and LOS. PsA is a highly heterogeneous disease and
measuring only one part may be misleading or lead to limited information for patients and
clinicians. Importantly, most of these domains are currently being measured in RCTs (9).
However, examination for areas of overlap is important to decrease redundancy.
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Next steps include investigation of instruments available to measure the Core Domain Set.
We are beginning this process with an SLR of instruments for each core domain. We will
investigate psychometric properties of available instruments such as face and content
validity (including match with the domain of interest) and feasibility as a part of the recently
described OMERACT decision making process for selection of outcome measures or “the
eyeball test” (23). Focus groups will take into account patient’s impressions of the
instruments. We will simultaneously examine instrument construct validity and
responsiveness in RCT datasets and LOS currently in progress. These work streams will
inform the development of a PsA Core Outcome Measurement set.
Additionally, the research agenda included items of importance to patients: independence,
sleep, stiffness and treatment burden. These domains need further study of their contribution
to PsA assessment.
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In summary, the updated PsA Core Domain set incorporates patient input, scientific
knowledge on pathophysiologic manifestations and measurement of disease in PsA, and the
broad life impact of PsA. Next steps include development of a PsA Core Outcome
Measurement set for RCTs and LOS.
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Figure 1.

Domains are shown on the X axis with proportion of studies measuring each domain on the
Y axis. The black mark designates 2006 PsA core domains. RCT: randomized controlled
trials; LOS: longitudinal observational studies; HRQL: health-related quality of life; MD:
physician; MRI: magnetic resonance imaging; US: ultrasound.
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Figure 2.
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Updated 2016 PsA Core Domain Set. MSK disease activity includes peripheral joints,
enthesitis, dactylitis, and spine symptoms. Skin activity includes skin and nails. PtGA is
defined as patient-reported diseaserelated health status. The inner circle includes domains
recommended for measurement in every RCT and LOS. The middle circle includes domains
that are important, but not required in every RCT and LOS. The outer circle contains
domains that may be important, but need further study. PsA: psoriatic arthritis; MSK:
musculoskeletal; PtGA: patient’s global assessment; RCT: randomized controlled trial; LOS:
longitudinal observational studies. Reproduced with permission from Orbai, et al. Ann
Rheum Dis 2016 Dec 13(E-pub ahead of print).
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Updated PsA Core Domain Set and corresponding OMERACT core areas. Domains in bold
face are in the core set (to be measured in all RCT), and domains in plain font are in the
middle circle (highly recommended, but not mandatory). PsA: psoriatic arthritis;
OMERACT: Outcome Measures in Rheumatology; RCT: randomized controlled trial;
HRQOL: health-related quality of life; MSK: musculoskeletal. From Boers M, et al. J Clin
Epidemiol 2014;67:745-53; adapted with permission.
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Domains in the 2006 PsA Core Domain Set and candidate domains for the updated core set
OMERACT 2006
PsA Core
Domain Set

OMERACT 2014
voted (≥70%)
inclusion in
the core set

Draft core domain set
at the end of the NGT*
meeting 2016

Draft core set after
the 2nd patient and physician
survey**

Peripheral joint activity

Dactylitis

MSK disease activity

MSK disease activity

Skin activity

Skin disease activity

Skin disease activity

Pain

Pain

Pain

Patient global

Patient global

Patient global

Physical function

Physical function

Physical function

Participation

Participation

HRQoL

Emotional well-being

Author Manuscript

Fatigue

Fatigue

Fatigue

Systemic inflammation

Systemic inflammation

Structural damage ***

Structural damage ***

*

NGT nominal group technique meeting,

**

during the second survey patients and physicians rated the importance of domains proposed after the NGT meeting – emotional well-being was
moved out of the core as less than 70% of either physician or patient respondents rated it as at least 8 on a scale from 0–10,

***

structural damage was recommended for assessment at least once during the development of a new drug for PsA.
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Patients involved in the PsA Core Domain Set update
Country

International patient
focus group
participants

Australia

7

Brazil

12

Canada
France

Qualitative data
analysis (patient
researchers, PRPs)

1
12

Survey participants

Nominal group
technique patient
participants and
PRPs

1

1

1

2

4

Hong Kong

1

Ireland

9

Italy
Netherlands

1

1

Author Manuscript

1

1

Norway

1

1

Romania

1

Singapore

17

2

13

8

Spain

1

UK

41

2

3

1

USA

27

1

18

4

Total

129

6

50

12
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Summary of core domain discussion during PsA workshop breakout groups at OMERACT 2016

Author Manuscript
Author Manuscript
Author Manuscript

Domain

Support inclusion

Challenges

Suggestions

Structural damage

Important aspect of medication
efficacy for PsA. Keep a special
status in the middle core with
requirement to be measured at least
once during the development
program of a new drug for PsA.

Not feasible to require in all
RCTs. Small changes if any
(no responsiveness) in short
clinical trials.

Combining modalities of
assessment is important.
Measurement instruments
may concomitantly assess
damage, inflammation and
disease activity

Systemic inflammation

Important, majority in all groups
supported inclusion. Also very
important in longitudinal studies due
to link with heart disease and
potentially other comorbidities.

-

When considering
instruments also consider
imaging for this domain

Emotional well-being

Very important to patients: important
in qualitative research and patient
surveys. Psychological distress is
frequent in both psoriasis and
psoriatic arthritis. Together with
participation and fatigue an
appropriate replacement for HRQoL.

Feasibility concern and
concern over necessity in
every RCT. Multifactorial
concept potentially
overlapping with patient
global and fatigue. How is it
different from HRQoL? This
could be an important/key
contextual factor.

We need to better
understand overlap with
patient global and HRQoL.
We also need to find
instruments for assessment.
Emotional well-being should
be examined as a
contextual factor.

MSK disease activity

Majority agreement with the updated
comprehensive MSK disease
activity. Easily comprehensible as a
domain even for nonrheumatologists.

Inclusion of spine symptoms
within MSK disease activity
is challenging due to the lack
of good instruments to
assess activity; additionally,
measuring spine symptoms
in all trials is not currently
feasible. Some preferred the
individual components be
considered instead of the
broader domain of MSK
disease activity.

Participation

Face validity: important to patients
and physicians, shows ability to “live
one’s life”. A common discussion
point was that participation is really
at the core of why we treat patients:
to improve their function in their
daily lives. Participation can be
measured and it is responsive. Work
and employment are very important
for patients. This is distinct from
physical function. However, this is
also more than just work and
includes social and leisure activities.

The definition as proposed is
broad. There was a concern
for overlap with HRQoL and
physical function, and it may
be influenced by emotional
well-being. Concern for
redundancy if also including
HRQoL in inner core. Some
thought it should be one or
the other.

Skin disease activity

Majority agreement, important to
patients and physicians

Some concerned about
feasibility of measuring in all
RCTs

Patient global
assessment

Always measured

Problematic to pinpoint the
exact concept behind this
domain

Physician global

N/A

Felt to be captured in MSK
disease activity. Potentially
subject to bias.

Proposed core set

Felt to be comprehensive. A
strength is that most of these
domains are already measured in
clinical trials.

Some participants felt the
core set contained too many
domains, potentially limiting
feasibility. There was a
concern for responder
burden at the measurement
stage.

Include in the inner core
and move HRQoL in the
middle circle. Study the
independent contribution of
the domain in explaining
PsA variability; and overlap
with other domains.

The patient global needs to
be addressed among all
diseases and should be
further studied.

Examine PROMIS
measures
Examine redundancies
among domains.
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81
55
31
-

Participation

Emotional wellbeing

Structural damage

-

57

32

14

6

8

No (%)

-

13

13

4

4

7

Insufficient
evidence or
information (%)

79

77

74

-

-

-

Yes (%)

15

17

19

-

-

-

No (%)

5

5

7

-

-

-

Insufficient
evidence or
information (%)

The number of OMERACT participants who voted for each question ranged from 132 to 138.

*

91

Systemic
inflammation

85

Skin activity

MSK disease
activity

Votes*

Yes (%)

Inner core position

Middle circle position
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Domain

Author Manuscript

Voting results at the conclusion of the PsA workshop
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